PCR Technology to Identify Minimal Residual Disease

Area of Science:

• Molecular Biology
• Oncology
• Clinical Diagnostics

Background:

• Minimal Residual Disease (MRD) monitoring is crucial for assessing treatment efficacy in hematologic malignancies.
• While novel techniques emerge, DNA-based allele-specific quantitative PCR (RQ-PCR) offers unparalleled sensitivity and accuracy for IG/TR gene targets.
• Detecting as few as 1 leukemic cell in 100,000 normal cells is achievable with current RQ-PCR methods.

Purpose of the Study:

• To describe the standardized DNA-based allele-specific RQ-PCR procedure for IG/TR MRD monitoring.
• To highlight the role of the EuroMRD Consortium in developing and refining this gold standard technique over two decades.
• To emphasize the ongoing provision of education, standardization, quality control, and interpretation guidelines.

Main Methods:

• Standardization of DNA-based allele-specific RQ-PCR protocols.
• Implementation of quality control rounds and educational activities by the EuroMRD Consortium.
• Minor laboratory-specific modifications to the established PCR procedure.

Main Results:

• DNA-based allele-specific RQ-PCR is confirmed as the gold standard for IG/TR MRD monitoring.
• The method allows for highly sensitive detection of residual leukemia cells.
• The EuroMRD Consortium has successfully maintained and disseminated a standardized protocol for 20 years.

Conclusions:

• Standardized DNA-based allele-specific RQ-PCR is essential for sensitive and accurate IG/TR MRD monitoring.
• The EuroMRD Consortium's collaborative efforts have ensured the continued reliability and accessibility of this critical diagnostic tool.
• Ongoing standardization and quality control are vital for maintaining the gold standard in MRD detection.